Male Reproductive System Neoplasm

subtype

Identifier: CI-CAN-00001107
Entity page: /cancer/male-reproductive-system-neoplasm ↗
Edges: 7,487

Neighbours: 15 genes20 drugs10 trials
Drawn: 45 of 45 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Male Reproductive System Neoplasm approved for …APPROVED_FORderived15 of 81show all (up to 200)
← approved for	Etoposidesmall molecule FDA (US) · approved · 2026-02-13 · Refractory testicular cancer	—	approved	Malignant Testicular Neoplasm	1	Regulatory	openfda	graph →
← approved for

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

ATM Mutation OlaparibFDA US 2017-08-1718 active / 42 trials
Curatedlevel Asensitivity· support 2civicObservedATM altered in 4.2% (86 / 2,069 cases, largest of 8 cohorts)Regulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Malignant Prostate Neoplasm, Castration-Resistant Prostate Carcinoma
BRCA2 Mutation OlaparibFDA US 2017-08-1718 active / 42 trials
Curatedlevel Asensitivity· support 2civicObservedBRCA2 altered in 3.6% (74 / 2,069 cases, largest of 7 cohorts)Regulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Malignant Prostate Neoplasm, Castration-Resistant Prostate Carcinoma
BRCA1 Mutation OlaparibFDA US 2017-08-1718 active / 42 trials
Curatedlevel Asensitivity· support 2civicObservedcohort frequency not yet available for BRCA1 in this cancerRegulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Malignant Prostate Neoplasm, Castration-Resistant Prostate Carcinoma
CDK12 Mutation OlaparibFDA US 2017-08-1718 active / 42 trials
Curatedlevel Asensitivity· support 1civicObservedCDK12 altered in 5.7% (118 / 2,069 cases, largest of 7 cohorts)Regulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Castration-Resistant Prostate Carcinoma
CHEK2 mutation OlaparibFDA US 2017-08-1718 active / 42 trials
Curatedlevel Asensitivity· support 1civicObservedCHEK2 altered in 4.2% (21 / 499 cases)Regulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Castration-Resistant Prostate Carcinoma
BRCA2 Mutation RucaparibFDA US 2016-12-192 active / 11 trials
Curatedlevel Asensitivity· support 1civicObservedBRCA2 altered in 3.6% (74 / 2,069 cases, largest of 7 cohorts)Regulatoryapproved for Castration-Resistant Prostate Carcinomacontext: Castration-Resistant Prostate Carcinoma
BARD1 Mutation OlaparibFDA US 2017-08-1718 active / 42 trials
Curatedlevel Asensitivity· support 1civicObservedcohort frequency not yet available for BARD1 in this cancerRegulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Castration-Resistant Prostate Carcinoma
BRCA1 Mutation RucaparibFDA US 2016-12-192 active / 11 trials
Curatedlevel Asensitivity· support 1civicObservedcohort frequency not yet available for BRCA1 in this cancerRegulatoryapproved for Castration-Resistant Prostate Carcinomacontext: Castration-Resistant Prostate Carcinoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Male Reproductive System Neoplasm altered in cohorts of …ALTERED_INderived15 of 242show all (up to 200)
← altered in cohorts of	KRAS 255 / 263 cases (97 %) · ssm · TCGA-TGCT	—	—	Testicular Germ Cell Tumor	1	Observed	gdc	graph →
← altered in cohorts of	ANO2 254 / 263 cases (97 %) · ssm · TCGA-TGCT	—	—	Testicular Germ Cell Tumor	1	Observed	gdc	graph →
← altered in cohorts of	ARHGDIB 254 / 263 cases (97 %) · ssm · TCGA-TGCT	—	—	Testicular Germ Cell Tumor	1	Observed	gdc	graph →
← altered in cohorts of	ART4 254 / 263 cases (97 %) · ssm · TCGA-TGCT	—	—	Testicular Germ Cell Tumor	1	Observed	gdc	graph →
← altered in cohorts of	ATF7IP 254 / 263 cases (97 %) · ssm · TCGA-TGCT	—	—	Testicular Germ Cell Tumor	1	Observed	gdc	graph →
← altered in cohorts of	C12orf60 254 / 263 cases (97 %) · ssm · TCGA-TGCT	—	—	Testicular Germ Cell Tumor	1	Observed	gdc	graph →
← altered in cohorts of	CAPZA3 254 / 263 cases (97 %) · ssm · TCGA-TGCT	—	—	Testicular Germ Cell Tumor	1	Observed	gdc	graph →
← altered in cohorts of	DERA 254 / 263 cases (97 %) · ssm · TCGA-TGCT	—	—	Testicular Germ Cell Tumor	1	Observed	gdc	graph →
← altered in cohorts of	EMP1 254 / 263 cases (97 %) · ssm · TCGA-TGCT	—	—	Testicular Germ Cell Tumor	1	Observed	gdc	graph →
← altered in cohorts of	EPS8 254 / 263 cases (97 %) · ssm · TCGA-TGCT	—	—	Testicular Germ Cell Tumor	1	Observed	gdc	graph →
← altered in cohorts of	ERP27 254 / 263 cases (97 %) · ssm · TCGA-TGCT	—	—	Testicular Germ Cell Tumor	1	Observed	gdc	graph →
← altered in cohorts of	FAM234B 254 / 263 cases (97 %) · ssm · TCGA-TGCT	—	—	Testicular Germ Cell Tumor	1	Observed	gdc	graph →
← altered in cohorts of	GPRC5D 254 / 263 cases (97 %) · ssm · TCGA-TGCT	—	—	Testicular Germ Cell Tumor	1	Observed	gdc	graph →
← altered in cohorts of	GRIN2B 254 / 263 cases (97 %) · ssm · TCGA-TGCT	—	—	Testicular Germ Cell Tumor	1	Observed	gdc	graph →
← altered in cohorts of	GSG1 254 / 263 cases (97 %) · ssm · TCGA-TGCT	—	—	Testicular Germ Cell Tumor	1	Observed	gdc	graph →

Male Reproductive System Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 268show all (up to 200)
→ investigated in trials for	Docetaxelsmall molecule 270 trials (47 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Neoplasm	270	Observed	clinicaltrials	graph →
→ investigated in trials for	Prednisonesmall molecule 230 trials (52 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Neoplasm	230	Observed	clinicaltrials	graph →
→ investigated in trials for	Enzalutamidesmall molecule 225 trials (80 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Neoplasm	225	Observed	clinicaltrials	graph →
→ investigated in trials for	Leuprolideother 138 trials (30 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Neoplasm	138	Observed	clinicaltrials	graph →
→ investigated in trials for	Abiraterone Acetatesmall molecule 136 trials (45 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Neoplasm	136	Observed	clinicaltrials	graph →
→ investigated in trials for	Bicalutamidesmall molecule 114 trials (18 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Neoplasm	114	Observed	clinicaltrials	graph →
→ investigated in trials for	Goserelinother 96 trials (17 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Neoplasm	96	Observed	clinicaltrials	graph →
→ investigated in trials for	Degarelixother 92 trials (20 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Neoplasm	92	Observed	clinicaltrials	graph →
→ investigated in trials for	Apalutamidesmall molecule 91 trials (44 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Neoplasm	91	Observed	clinicaltrials	graph →
→ investigated in trials for	Abirateronesmall molecule 90 trials (37 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Neoplasm	90	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 71 trials (21 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Neoplasm	71	Observed	clinicaltrials	graph →
→ investigated in trials for	Darolutamidesmall molecule 62 trials (41 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Neoplasm	62	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 56 trials (21 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Neoplasm	56	Observed	clinicaltrials	graph →
→ investigated in trials for	Cabazitaxelsmall molecule 54 trials (16 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Neoplasm	54	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 49 trials (11 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Neoplasm	49	Observed	clinicaltrials	graph →

Male Reproductive System Neoplasm studied in …STUDIED_INderived10 of 6,896show all (up to 200)
→ studied in	NCT01230866Phase 3 · active not recruiting Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer · condition mapped CURATED_EXACT · 6,896 trials mapped (1,951 active)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT01242072Phase 1 · completed Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies · condition mapped CURATED_EXACT · 6,896 trials mapped (1,951 active)	—	—	Malignant Testicular Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT01492972Phase 3 · recruiting Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer · condition mapped CURATED_EXACT · 6,896 trials mapped (1,951 active)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 6,896 trials mapped (1,951 active)	—	—	Prostate Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 6,896 trials mapped (1,951 active)	—	—	Malignant Testicular Leydig Cell Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT04736199Phase 3 · completed Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer · condition mapped ALIAS · 6,896 trials mapped (1,951 active)	—	—	Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05081193Phase 2 · active not recruiting Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer · condition mapped CURATED_EXACT · 6,896 trials mapped (1,951 active)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05148156NA · recruiting Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer. · condition mapped ONTOLOGY_EXACT · 6,896 trials mapped (1,951 active)	—	—	Benign Prostatic Hyperplasia	1	Observed	clinicaltrials	graph →
→ studied in	NCT06011304Phase 3 · completed Study of 18F-Florastamin PET/CT Imaging in Patients With at Least Intermediate Risk Prostate Cancer · condition mapped CURATED_EXACT · 6,896 trials mapped (1,951 active)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06541210NA · recruiting Building Community Living Labs in Black Communities to Advance Prostate Health Equity and Reduce Prostate Cancer Disparities in Black Men · condition mapped ONTOLOGY_EXACT · 6,896 trials mapped (1,951 active)	—	—	Prostate Carcinoma	1	Observed	clinicaltrials	graph →